Term | Conceptual Definition |
Cancer Education Grant | Grant mechanism to support: innovative educational programs intended to motivate biomedical and other health science students to pursue cancer related careers; short courses to update cancer research scientists in new scientific methods, technologies and findings; training of cancer care clinicians and community health care providers in evidence-based cancer prevention and control approaches; development of effective innovative education (dissemination) approaches to translate knowledge gained from science (discovery) into public health and community applications (delivery).
|
Career Development Award (CDA K Series) | Awards for candidates who wish to further develop their careers in biomedical, behavioral and clinical research. Applicants are generally required to hold a research or health–professional doctoral degree or its equivalent; eligibility for some CDAs is limited to only applicants with health professional doctoral degrees. |
Clinical Research | Research with human subjects that is: 1. Patient-oriented research. Research conducted with human subjects (or on material of human origin such as tissues, specimens, and cognitive phenomena) for which an investigator (or colleague) directly interacts with human subjects. Excluded from this definition are in vitro studies that utilize human tissues that cannot be linked to a living individual. It includes: mechanisms of human disease, therapeutic interventions, clinical trials, development of new technologies 2. Epidemiological and behavioral studies. 3. Outcomes research and health services research. Studies falling under 45 CFR part 46.101(b) (4) (Exemption 4) are not considered clinical research by this definition. |
Clinical Trial
| "A biomedical or behavioral research study of human subjects designed to answer specific questions about biomedical or behavioral interventions (drugs, treatments, devices, or new ways of using known drugs, treatments, or devices). Clinical trials are used to determine whether new biomedical or behavioral interventions are safe, efficacious, and effective. Clinical trials of an experimental drug, treatment, device, or intervention may proceed through four phases:
Phase I. Testing in a small group of people (e.g. 20-80) to determine efficacy and evaluate safety (e.g., determine a safe dosage range and identify side effects).
Phase II. Study in a larger group of people (several hundred) to determine efficacy and further evaluate safety.
Phase III. Study to determine efficacy in large groups of people (from several hundred to several thousand) by comparing the intervention to other standard or experimental interventions, to monitor adverse effects, and to collect information to allow safe use.
Phase IV. Studies done after the intervention has been marketed. These studies are designed to monitor the effectiveness of the approved intervention in the general population and to collect information about any adverse effects associated with widespread use."
|
Co-Funding | Funding arrangement through which two or more Institutes or Centers share in the funding of a grant.
|
Co-Investigator | An individual involved with the PD/PI in the scientific development or execution of a project. The co-investigator (collaborator) may be employed by, or be affiliated with, the applicant/grantee organization or another organization participating in the project under a consortium agreement. A co-investigator typically devotes a specified percentage of time to the project and is considered senior/key personnel. The designation of a co-investigator, if applicable, does not affect the PD/PI’s roles and responsibilities as specified in the NIH Grants Policy Statement (NIH GPS), nor is it a role implying multiple PD/PI. |
Commitment Base | Funds used for noncompeting (type 5 or ongoing awards), typically 70-80 percent of the dollars spent for research project grants.
|
Comparative medicine center | A research center funding mechanism. Grants to support the development of mammalian and non-mammalian models for research, or to make animal or biological materials resources available to all qualified investigators. |
Competing Applications | New or renewal applications that must undergo initial peer review.
|
Competing Continuation | See Renewal |
Competitive Segment | The initial project period recommended for support (in general, up to 5 years) or each extension of a project period resulting from a renewal award. |
Constant Dollars | Dollar amounts adjusted for inflation, based on buying power in a selected base year. The BRDPI is used to determine constant dollars from current dollars.
|
Continuation | Financial or direct assistance for a second or subsequent budget period. |
Contract (R&D) | An award instrument used to acquire from a non-federal party, by purchase, lease, or barter, property or services for the direct benefit or use of the Federal government. The same term may be used to describe a vendor relationship between a recipient and another party under a grant (to acquire routine goods and services); however, the recipient may use subaward to describe the contract under a grant relationship. |
Cooperative Agreement (U Series) | A support mechanism used when there will be substantial Federal scientific or programmatic involvment. Substantial involvement means that after award, scientific or program staff will assist, guide, coordinate, or participate in project activities. |
Cooperative Research and Development Agreement (CRDA) | Any agreement between one or more NIH laboratories and one or more non-Federal parties under which the PHS, through its laboratories, provides personnel, services, facilities, equipment, or other resources with or without reimbursement (but not funds to non-Federal parties) and the non-Federal parties provide funds, personnel, services, facilities, equipment, or other resources toward the conduct of specified research or development efforts which are consistent with the missions of the laboratory.
|
Costs, Direct | Costs that can be specifically identified with a particular project or activity. |
Costs, Direct, Awarded | Total NIH direct cost dollars awarded to a grant. |
Costs, Direct, Requested | Principal Investigators request a funding level in their application for each year. These dollars are only direct costs and do not include the indirect cost associated with the organization where the research will be conducted. |
Costs, Indirect | Costs that are incurred by a grantee for common or joint objectives and cannot be identified specifically with a particular project or program. |
Costs, Indirect, Awarded
| Total NIH indirect cost dollars awarded to a grant.
|
Costs, Total, Awarded
| Total NIH dollars awarded to a grant.
|
Council Round
| At the NIH, there are at least three, and sometimes four, council rounds each fiscal year: October, January, May, and sometimes August. Application receipt dates, initial review dates, and council review dates all fall within one of these council rounds. Incoming grant applications all are assigned to a council round.
|
Count (application/award/grant)
| Unless noted, the total number of applications/grants shown, excluding administrative supplements.
|
Current dollars | Actual dollars awarded without adjustment for inflation.
|
1 |